Precision Dosing of Anti-TNF Therapy in Pediatric Inflammatory Bowel Disease.

ABSTRACT:

Purpose of the review

This review focuses on recent advancements in anti-TNF therapeutic drug monitoring (TDM), pharmacogenetics and personalized drug selection for children with inflammatory bowel disease (IBD).

Recent findings

Several real-world studies and one clinical trial in children have demonstrated that proactive TDM, targeting higher exposure concentrations (> 5 µg/mL), can improve disease remission rates and enhance durability of the anti-TNF biologics. Recent data from both adult and pediatric IBD patients have revealed an association between a genetic polymorphism (HLA-DQA1*05) and the development of auto-drug antibodies. The impact of this association on clinical outcomes, considering more routine use proactive TDM and dose optimization in children, is still un

SUBMITTER: Samuels A 

PROVIDER: S-EPMC10865142 | biostudies-literature | 2023 Nov

REPOSITORIES: biostudies-literature